Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
Genethon Advances Groundbreaking Gene Therapies for Patients with Rare Genetic Diseases [Yahoo! Finance]